Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

van Horssen R, Ten Hagen TL, Eggermont AM.

Oncologist. 2006 Apr;11(4):397-408. Review.

2.

Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities.

Grünhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM.

Nat Clin Pract Oncol. 2006 Feb;3(2):94-103. Review.

PMID:
16462850
3.

TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.

Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R.

Exp Cell Res. 2008 Feb 1;314(3):509-29. Epub 2007 Oct 13.

PMID:
18061162
4.

Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization.

Fotin-Mleczek M, Welte S, Mader O, Duchardt F, Fischer R, Hufnagel H, Scheurich P, Brock R.

J Cell Sci. 2005 Aug 1;118(Pt 15):3339-51.

5.

TNF signaling: early events and phosphorylation.

Ihnatko R, Kubes M.

Gen Physiol Biophys. 2007 Sep;26(3):159-67. Review.

PMID:
18063842
7.

The role of TNF in cancer.

Wajant H.

Results Probl Cell Differ. 2009;49:1-15. doi: 10.1007/400_2008_26. Review.

PMID:
19137269
8.
9.

Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects.

Gerspach J, Pfizenmaier K, Wajant H.

Biofactors. 2009 Jul-Aug;35(4):364-72. doi: 10.1002/biof.50. Review.

PMID:
19484741
10.

Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.

Kayton ML, Libutti SK.

Curr Opin Investig Drugs. 2001 Jan;2(1):136-8. Review.

PMID:
11527006
11.

[Tumor necrosis factor: pleiotropic cytokine].

Chouaib S, Robinet E, Zyad A, Branellec D.

Bull Cancer. 1992;79(10):935-49. Review. French.

PMID:
1292760
12.

[TNF: antitumoral agent at the border lines of immunity and inflammation].

Branellec D, Chouaib S.

Pathol Biol (Paris). 1991 Mar;39(3):230-9. Review. French.

PMID:
1646993
13.
15.

Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.

Reuss R, Pohle S, Retzlaff K, Hemberger J, Oschmann P.

Neuroimmunomodulation. 2009;16(3):171-6. doi: 10.1159/000204230. Epub 2009 Feb 24.

PMID:
19246939
16.

Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program.

Eggermont AM, Manusama ER, ten Hagen TL.

J Inflamm. 1995-1996;47(1-2):104-13. Review.

PMID:
8913937
17.

TNF: a master switch for inflammation to cancer.

Sethi G, Sung B, Aggarwal BB.

Front Biosci. 2008 May 1;13:5094-107. Review.

PMID:
18508572
18.

Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.

Hoving S, Seynhaeve AL, van Tiel ST, aan de Wiel-Ambagtsheer G, de Bruijn EA, Eggermont AM, ten Hagen TL.

Anticancer Drugs. 2006 Sep;17(8):949-59.

PMID:
16940805
19.

TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.

Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak TW, Ohashi PS.

J Clin Invest. 2007 Dec;117(12):3833-45.

20.

Effect of age on molecular signaling of TNF-alpha-induced apoptosis in human lymphocytes.

Gupta S, Chiplunkar S, Kim C, Yel L, Gollapudi S.

Mech Ageing Dev. 2003 Apr;124(4):503-9. Review.

PMID:
12714259

Supplemental Content

Support Center